The 2012 "toxic capsule" scandal that shook China's pharmaceutical industry uncovered a critical cost-driven loophole: to cut expenses, numerous small and medium-sized hollow capsule manufacturers turned to substandard copper-chromium plated molds instead of safe stainless steel alternatives-directly contributing to excessive chromium (a heavy metal) in finished products.
A stark price difference became the primary driver of this violation. The pre-tax price of imported stainless steel molds reached as high as 3.94 million yuan per set, while a set of copper-chromium plated molds cost merely over 200,000 yuan. Though the production capacity of copper-chromium plated molds was less than half that of the stainless steel ones, their extremely low initial investment threshold made them an irresistible choice for cash-strapped enterprises eager to enter the market.
Worse still, the market's regulatory oversight was severely inadequate at the time. Only 51 enterprises in China held formal production certificates compliant with national pharmaceutical standards. However, the actual number of manufacturers producing hollow capsules was dozens of times that figure-most operating without legal qualifications. The health product sector, in particular, emerged as the hardest-hit area for problematic capsules: unlike the strictly regulated pharmaceutical industry, health product production faced relatively lax supervision, turning it into a "safe haven" for unqualified manufacturers to offload capsules made with risky molds.
This scandal ultimately laid bare three fundamental pain points in the hollow capsule industry:
Lack of mandatory standards: There were no compulsory national standards for mold quality in the upstream supply chain, allowing low-quality, hazardous molds to circulate freely.
Poor corporate self-discipline: Many enterprises prioritized short-term profits over product safety, ignoring the health risks of using substandard equipment.
Dual responsibility gap: Pharmaceutical manufacturers failed to conduct strict inspections on the mold quality of their capsule suppliers, while regulatory authorities lacked sufficient oversight to curb illegal production in a timely manner.